Reduction of adverse effects by systemic antihistamines in drug therapy with fumarates in severe chronic plaque psoriasis: a doubleblind, randomized, placebo controlled clinical trial

Recruiting

• Conditions: fumarates; side-effects; 10014982

• Registration Number: NL-OMON37148
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

1)Patients with known severe psoriasis of the chronic plaque type
2)PASI >= 10
3)Age >= 18 years
4)Signed informed consent

Exclusion Criteria

1)Pregnancy and breast feeding
2)Patients with Prostate hyperplasia, Glaucoma, Stomach ulcer
3)Patients with liver diseases
4)Patients with kidney diseases
5)Patients with blood test deviations
6)Patients with gastro-intestinal diseases
7)Patients with a history of malignancies

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To attempt to decrease the side effects in patients by using fumarates in<br /><br>combination with antihistamines (Cetirizine). </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>We will attempt to show that antihistamines can also support fumarate therapy<br /><br>with an antipsoriatic effect through immunomodulation.</p><br>